SCHEMBL789339

SCHEMBL789339

COc1ccccc1OCCNC(Oc1cccc2[nH]c3ccccc3c12)C(C)O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 8/20 0.63
DRD2 P14416 3/20 0.63
TLR4 O00206 3/20 0.63
MAPT P10636 2/20 0.63
DNM1 Q05193 2/20 0.63
KDM4E B2RXH2 2/20 0.63
ADRB3 P13945 2/20 0.63
SLC22A2 O15244 1/20 0.63
SLC22A1 O15245 1/20 0.63
MLNR O43193 1/20 0.63
NR1I2 O75469 1/20 0.63
KCNK2 O95069 1/20 0.63
ABCB11 O95342 1/20 0.63
APP P05067 1/20 0.63
ABCB1 P08183 1/20 0.63
ADRB1 P08588 1/20 0.63
HTR1A P08908 1/20 0.63
ADRA2A P08913 1/20 0.63
ADORA3 P0DMS8 1/20 0.63
GAA P10253 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5674942 0.87 ADRB2 (0.58) ADRB2DRD2TLR4MAPTDNM1
SCHEMBL8587280 0.87 ADRB2 (0.54) ADRB2DRD2TLR4MAPTDNM1
SCHEMBL3710263 0.86 ADRB2 (0.57) ADRB2DRD2TLR4MAPTDNM1
SCHEMBL3388893 0.86 ADRB2 (0.57) ADRB2DRD2TLR4MAPTDNM1
SCHEMBL6507182 0.85 ADRB2 (0.54) ADRB2DRD2TLR4MAPTDNM1
SCHEMBL15874588 0.81 ADRB2 (0.72) ADRB2DRD2TLR4MAPTDNM1
SCHEMBL4457452 0.79 ADRB2 (0.53) ADRB2DRD2TLR4MAPTDNM1
SCHEMBL4436284 0.79 ADRB2 (0.55) ADRB2DRD2TLR4MAPTDNM1
SCHEMBL4608341 0.78 ADRB2 (0.53) ADRB2DRD2TLR4MAPTDNM1
SCHEMBL4605047 0.78 ADRB2 (0.45) ADRB2DRD2TLR4MAPTDNM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022117893-A2 COMBINATION THERAPY FOR PATIENTS HAVING ACUTE AND/OR PERSISTENT DYSPNEA S-FORM PHARMA (BE) 2022-06-09 WO claimed
EP-2970900-A1 COMPOUNDS FOR INDUCING PROLIFERATION AND DIFFERENTIATION OF CELLS, AND METHODS OF USE THEREOF The Broad Institute, Inc. (US) 2016-01-20 EP claimed
WO-2014144125-A1 COMPOUNDS FOR INDUCING PROLIFERATION AND DIFFERENTIATION OF CELLS, AND METHODS OF USE THEREOF THE BROAD INSTITUTE, INC. (US) 2014-09-18 WO claimed
WO-2004113296-A1 A PROCESS FOR PREPARATION OF 1-[9H-CARBAZOL-4-YLOXY]- 3-[{2-(2-(-(METHOXY)PHENOXY)-ETHYL}-AMINO]-PROPAN-2-OL SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) 2004-12-29 WO claimed
EP-1355880-A2 PROCESS FOR THE PREPARATION OF HETEROCYCLIC INDENE ANALOGS F. HOFFMANN-LA ROCHE AG (CH) 2003-10-29 EP claimed
WO-2002059089-A2 PROCESS FOR THE PREPARATION OF HETEROCYCLIC INDENE ANALOGS F. HOFFMANN-LA ROCHE AG (CH) 2002-08-01 WO claimed
WO-1998038986-A2 USE OF CARVEDILOL OR DERIVATIVES THEREOF FOR THE MANUFACTURE OF A MEDICAMENT FOR THE PREVENTION AND TREATMENT OF VIRAL INFECTIONS ROCHE DIAGNOSTICS GMBH (DE) 1998-09-11 WO claimed
EP-4309673-A2 FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE Bausch Health Ireland Limited (IE) 2024-01-24 EP disclosed
EP-3708179-B1 FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE BAUSCH HEALTH IRELAND LTD (IE) 2023-10-04 EP disclosed
WO-2022117893-A2 COMBINATION THERAPY FOR PATIENTS HAVING ACUTE AND/OR PERSISTENT DYSPNEA S-FORM PHARMA (BE) 2022-06-09 WO disclosed
EP-3989971-A1 NOVEL ANTIVIRAL THERAPIES Niklovir AB (SE) 2022-05-04 EP disclosed
WO-2020263151-A1 NOVEL ANTIVIRAL THERAPIES NIKLOVIR AB (SE) 2020-12-30 WO disclosed
US-20200283480-A1 AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS BAUSCH HEALTH COMPANIES INC. (CA) 2020-09-10 US disclosed
EP-0741567-A1 INHIBITION OF SMOOTH MUSCLE MIGRATION AND PROLIFERATION WITH HYDROXY CARBAZOLE COMPOUNDS BOEHRINGER MANNHEIM PHARMACEUTICALS CORPORATION-SMITHKLINE BEECHAM CORPORATION LIMITED PARTNERSHIP NO. 1 (US) 1996-11-13 EP disclosed
EP-0671913-A4 1995-10-25 EP disclosed
EP-0671913-A1 ANTIOXYDANT CARDIOPROTECTIVE USE OF, AND METHOD OF TREATMENT USING, HYDROXYCARBAZOLE COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 1995-09-20 EP disclosed
WO-1995014384-A1 INHIBITION OF SMOOTH MUSCLE MIGRATION AND PROLIFERATION WITH HYDROXY CARBAZOLE COMPOUNDS BOEHRINGER MANNHEIM PHARMACEUTICALS (US) 1995-06-01 WO disclosed
WO-1994020097-A1 USE OF, AND METHOD OF TREATMENT USING, CARBAZOLYL-(4)-OXYPROPANOLAMINE COMPOUNDS FOR INHIBITION OF SMOOTH MUSCLE CELL PROLIFERATION BOEHRINGER MANNHEIM PHARMACEUTICALS CORPORATION-SMITHKLINE BEECHAM CORPORATION LIMITED PARTNERSHIP NO. 1 (US) 1994-09-15 WO disclosed
WO-1994020096-A1 METHOD OF EMPLOYING CARBAZOLYL-(4)-OXYPROPANOLAMINE COMPOUNDS FOR INHIBITION OF SMOOTH MUSCLE CELL PROLIFERATION BOEHRINGER MANNHEIM PHARMACEUTICALS CORPORATION - SMITHKLINE BECKMAN CORPORATION LIMITED (US) 1994-09-15 WO disclosed
WO-1994012177-A1 ANTIOXYDANT CARDIOPROTECTIVE USE OF, AND METHOD OF TREATMENT USING, HYDROXYCARBAZOLE COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 1994-06-09 WO disclosed